Recent advances in comprehending the signaling pathways involved in the progression of breast cancer

International Journal of Molecular Sciences

Volumn 18, Issue 11, 2017, Pages

  Nicolini, Andrea ^a   Ferrari, Paola ^a   Diodati, Lucrezia ^a   Carpi, Angelo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Breast cancer; Calcium sensing receptor; Cancer progression; Caveolae; Hypoxia inducing factors; Personalized medicine; Signaling pathways

Indexed keywords

CALCIUM SENSING RECEPTOR; CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; HEPARIN; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 6; MICRORNA; MICRORNA 378A 5P; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PLASMA MEMBRANE CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ERBB2 PROTEIN, HUMAN;

ANGIOGENESIS; BREAST CANCER; BREAST DEVELOPMENT; CALCIUM ABSORPTION; CALCIUM SIGNALING; CANCER GROWTH; CAVEOLA; CELL DEATH; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FATTY ACID SYNTHESIS; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; MAMMARY GLAND; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OXIDATIVE STRESS; PARATHYROID GLAND; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UBIQUITINATION; ANIMAL; BREAST; BREAST TUMOR; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BREAST; BREAST NEOPLASMS; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 85033586521     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18112321     Document Type: Review

References (115)

1. Verigos, J.; Magklara, A. Revealing the Complexity of Breast Cancer by Next Generation Sequencing. Cancers 2015, 7, 2183-2200.
2. Yachida, S.; Jones, S.; Bozic, I.; Antal, T.; Leary, R.; Fu, B.; Kamiyama, M.; Hruban, R.H.; Eshleman, J.R.; Nowak, M.A.; et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467, 1114-1117.
3. Zardavas, D.; Irrthum, A.; Swanton, C.; Piccart, M. Clinical management of breast cancer heterogeneity. Nat. Rev. Clin. Oncol. 2015, 12, 381-394.
4. Wang, Y.; Waters, J.; Leung, M.L.; Unruh, A.; Roh, W.; Shi, X.; Chen, K.; Scheet, P.; Vattathil, S.; Liang, H.; et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014, 512, 155-160.
5. Mimeault, M.; Batra, S.K. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol. Histopathol. 2010, 25, 1057-1073.
6. Mimeault, M.; Batra, S.K. Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J. Clin. Oncol. 2012, 3, 32-42.
7. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
8. Bräuner-Osborne, H.; Wellendorph, P.; Jensen, A.A. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr. Drug Targets 2007, 8, 169-184.
9. 2+-sensing receptor from bovine parathyroid. Nature 1993, 366, 575-580.
10. Brown, E.M.; MacLeod, R.J. Extracellular calcium sensing and extracellular calcium signalling. Physiol. Rev. 2001, 81, 239-297.
11. Brennan, S.C.; Thiem, U.; Roth, S.; Aggarwal, A.; Fetahu, I.S.; Tennakoon, S.; Gomes, A.R.; Brandi, M.L.; Bruggeman, F.; Mentaverri, R.; et al. Calcium sensing receptor signalling in physiology and cancer. Biochim. Biophys. Acta 2013, 1833, 1732-1744.
12. Kim, W.; Wysolmerski, J.J. Calcium-Sensing Receptor in Breast Physiology and Cancer. Front. Physiol. 2016, 7, 440.
13. Wysolmerski, J.J. Parathyroid hormone-related protein: An update. J. Clin. Endocrinol. Metab. 2012, 97, 2947-2956.
14. Cheng, I.; Klingensmith, M.E.; Chattopadhyay, N.; Kifor, O.; Butters, R.R.; Soybel, D.I.; Brown, E.M. Identification and localization of the extracellular calcium-sensing receptor in human breast. J. Clin. Endocrinol. Metab. 1998, 83, 703-707.
15. VanHouten, J.; Dann, P.; McGeoch, G.; Brown, E.M.; Krapcho, K.; Neville, M.; Wysolmerski, J.J. The calcium-sensing receptor regulates mammary gland parathyroid hormone-related protein production and calcium transport. J. Clin. Investig. 2004, 113, 598-608.
16. Mamillapalli, R.; VanHouten, J.; Zawalich, W.; Wysolmerski, J. Switching of G-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells. J. Biol. Chem. 2008, 283, 24435-24447.
17. VanHouten, J.N.; Wysolmerski, J.J. Transcellular calcium transport in mammary epithelial cells. J. Mammary Gland Biol. Neoplasia 2007, 12, 223-235.
18. Sanders, J.L.; Chattopadhyay, N.; Kifor, O.; Yamaguchi, T.; Butters, R.R.; Brown, E.M. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 2000, 141, 4357-4364.
19. Kim, W.; Takyar, F.M.; Swan, K.; Jeong, J.; VanHouten, J.; Sullivan, C.; Dann, P.; Yu, H.; Fiaschi-Taesch, N.; Chang, W.; et al. Calcium-Sensing Receptor Promotes Breast Cancer by Stimulating Intracrine Actions of Parathyroid Hormone-Related Protein. Cancer Res. 2016, 76, 5348-5360.
20. Li, X.; Kong, X.; Jiang, L.; Ma, T.; Yan, S.; Yuan, C.; Yang, Q. A genetic polymorphism (rs17251221) in the calcium-sensing receptor is associated with breast cancer susceptibility and prognosis. Cell. Physiol. Biochem. 2014, 33, 165-172.
21. Li, X.; Li, L.; Moran, M.S.; Jiang, L.; Kong, X.; Zhang, H.; Zhang, X.; Haffty, B.G.; Yang, Q. Prognostic significance of calcium-sensing receptor in breast cancer. Tumour Biol. 2014, 35, 5709-5715.
22. 2+-sensing receptor, Gα12 and Rho-dependent in breast cancer cells. Cell Signal. 2009, 21, 1894-1900.
23. Vanhouten, J.N.; Wysolmerski, J.J. The calcium-sensing receptor in the breast. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27, 403-414.
24. Mihai, R.; Stevens, J.; McKinney, C.; Ibrahim, N.B. Expression of the calcium receptor in human breast cancer-A potential new marker predicting the risk of bone metastases. Eur. J. Surg. Oncol. 2006, 32, 511-515.
25. Camp, R.L.; Chung, G.G.; Rimm, D.L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 2002, 8, 1323-1327.
26. Yao, S.; Haddad, S.A.; Hu, Q.; Liu, S.; Lunetta, K.L.; Ruiz-Narvaez, E.A.; Hong, C.C.; Zhu, Q.; Sucheston-Campbell, L.; Cheng, T.Y.; et al. Genetic variations in vitamin D-related pathways and breast cancer risk in African American women in the AMBER consortium. Int. J. Cancer 2016, 138, 2118-2126.
27. Promkan, M.; Liu, G.; Patmasiriwat, P.; Chakrabarty, S. BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells. Cell Calcium 2011, 49, 79-88.
28. El Hiani, Y.; Ahidouch, A.; Lehen’kyi, V.; Hague, F.; Gouilleux, F.; Mentaverri, R.; Kamel, S.; Lassoued, K.; Brûlé, G.; Ouadid-Ahidouch, H. Extracellular signal-regulated kinases 1 and 2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7 breast cancer cell proliferation. Cell. Physiol. Biochem. 2009, 23, 335-346.
29. Yano, S.; Macleod, R.J.; Chattopadhyay, N.; Tfelt-Hansen, J.; Kifor, O.; Butters, R.R.; Brown, E.M. Calcium-sensing receptor activation stimulates parathyroid hormone-related protein secretion in prostate cancer cells: Role of epidermal growth factor receptor transactivation. Bone 2004, 35, 664-672.
30. Tomlins, S.A.; Bollinger, N.; Creim, J.; Rodland, K.D. Cross-talk between the calcium-sensing receptor and the epidermal growth factor receptor in Rat-1 fibroblasts. Exp. Cell Res. 2005, 308, 439-445.
31. Shah, T.; Wildes, F.; Penet, M.F.; Winnard, P.T., Jr.; Glunde, K.; Artemov, D.; Ackerstaff, E.; Gimi, B.; Kakkad, S.; Raman, V.; et al. Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed. 2010, 23, 633-642.
32. Baio, G.; Rescinito, G.; Rosa, F.; Pace, D.; Boccardo, S.; Basso, L.; Salvi, S.; Calabrese, M.; Truini, M.; Neumaier, C.E. Correlation between Choline Peak at MR Spectroscopy and Calcium-Sensing Receptor Expression Level in Breast Cancer: A Preliminary Clinical Study. Mol. Imaging Biol. 2015, 17, 548-556.
33. Liu, G.; Hu, X.; Chakrabarty, S. Calcium sensing receptor down-regulates malignant cell behavior and promotes chemosensitivity in human breast cancer cells. Cell Calcium 2009, 45, 216-225.
34. Boudot, C.; Hénaut, L.; Thiem, U.; Geraci, S.; Galante, M.; Saldanha, P.; Saidak, Z.; Six, I.; Clézardin, P.; Kamel, S.; et al. Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. Oncotarget 2017, 8, 56460-56472.
35. Zhu, J.; Jia, X.; Xiao, G.; Kang, Y.; Partridge, N.C.; Qin, L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: Implications for osteolytic bone metastases. J. Biol. Chem. 2007, 282, 26656-26664.
36. Tao, N.; Wagner, S.J.; Lublin, D.M. CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails. J. Biol. Chem. 1996, 271, 22315-22320.
37. Dietzen, D.J.; Hastings, W.R.; Lublin, D.M. Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of caveolin to caveolae. J. Biol. Chem. 1995, 270, 6838-6842.
38. Parton, R.G.; Way, M.; Zorzi, N.; Stang, E. Caveolin-3 associates with developing T-tubules during muscle differentiation. J. Cell Biol. 1997, 136, 137-154.
39. Parton, R.G.; del Pozo, M.A. Caveolae as plasma membrane sensors, protectors and organizers. Nat. Rev. Mol. Cell Biol. 2013, 14, 98-112.
40. Frank, P.G.; Cheung, M.W.; Pavlides, S.; Llaverias, G.; Park, D.S.; Lisanti, M.P. Caveolin-1 and regulation of cellular cholesterol homeostasis. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, 677-686.
41. Bosch, M.; Marí, M.; Herms, A.; Fernández, A.; Fajardo, A.; Kassan, A.; Giralt, A.; Colell, A.; Balgoma, D.; Barbero, E.; et al. Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. Curr. Biol. 2011, 21, 681-686.
42. Trimmer, C.; Sotgia, F.; Whitaker-Menezes, D.; Balliet, R.M.; Eaton, G.; Martinez-Outschoorn, U.E.; Pavlides, S.; Howell, A.; Iozzo, R.V.; Pestell, R.G.; et al. Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biol. Ther. 2011, 11, 383-394.
43. Martinez-Outschoorn, U.E.; Sotgia, F.; Lisanti, M.P. Caveolae and signalling in cancer. Nat. Rev. Cancer 2015, 15, 225-237.
44. Martinez-Outschoorn, U.E.; Lisanti, M.P.; Sotgia, F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 2014, 25, 47-60.
45. Whitaker-Menezes, D.; Martinez-Outschoorn, U.E.; Lin, Z.; Ertel, A.; Flomenberg, N.; Witkiewicz, A.K.; Birbe, R.C.; Howell, A.; Pavlides, S.; Gandara, R.; et al. Evidence for a stromal-epithelial lactate shuttle in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011, 10, 1772-1783.
46. Savage, K.; Lambros, M.B.; Robertson, D.; Jones, R.L.; Jones, C.; Mackay, A.; James, M.; Hornick, J.L.; Pereira, E.M.; Milanezi, F.; et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin. Cancer Res. 2007, 13, 90-101.
47. Mercier, I.; Camacho, J.; Titchen, K.; Gonzales, D.M.; Quann, K.; Bryant, K.G.; Molchansky, A.; Milliman, J.N.; Whitaker-Menezes, D.; Sotgia, F.; et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: Chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am. J. Pathol. 2012, 181, 278-293.
48. Fong, G.H.; Takeda, K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ. 2008, 15, 635-641.
49. D’Alterio, C.; Barbieri, A.; Portella, L.; Palma, G.; Polimeno, M.; Riccio, A.; Ieranò, C.; Franco, R.; Scognamiglio, G.; Bryce, J.; et al. Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol. Immunother. 2012, 61, 1713-1720.
50. Kaelin, W.G., Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 2004, 10, 6290S-6295S.
51. D’Ignazio, L.; Batie, M.; Rocha, S. Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. Biomedicines 2017, 5, 21.
52. Partch, C.L.; Gardner, K.H. Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B. Proc. Natl. Acad. Sci. USA 2011, 108, 7739-7744.
53. Mimeault, M.; Batra, S.K. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J. Cell. Mol. Med. 2013, 17, 30-54.
54. Jubb, A.M.; Buffa, F.M.; Harris, A.L. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J. Cell. Mol. Med. 2010, 14, 18-29.
55. Giuntoli, S.; Tanturli, M.; di Gesualdo, F.; Barbetti, V.; Rovida, E.; Dello Sbarba, P. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate. Haematologica 2011, 96, 204-212.
56. -/low breast ductal carcinomas. Diagn. Pathol. 2011, 6, 73.
57. Quail, D.F.; Taylor, M.J.; Walsh, L.A.; Dieters-Castator, D.; Das, P.; Jewer, M.; Zhang, G.; Postovit, L.M. Low oxygen levels induce the expression of the embryonic morphogen Nodal. Mol. Biol. Cell. 2011, 22, 4809-4821.
58. Conley, S.J.; Gheordunescu, E.; Kakarala, P.; Newman, B.; Korkaya, H.; Heath, A.N.; Clouthier, S.G.; Wicha, M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. USA 2012, 109, 2784-2789.
59. - cells through SDF-1/CXCR4 interaction. J. Exp. Clin. Cancer Res. 2010, 29, 80.
60. Wong, C.C.; Gilkes, D.M.; Zhang, H.; Chen, J.; Wei, H.; Chaturvedi, P.; Fraley, S.I.; Wong, C.M.; Khoo, U.S.; Ng, I.O.; et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl. Acad. Sci. USA 2011, 108, 16369-16374.
61. Erler, J.T.; Bennewith, K.L.; Cox, T.R.; Lang, G.; Bird, D.; Koong, A.; Le, Q.T.; Giaccia, A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15, 35-44.
62. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
63. -/lower phenotype metastasis to human bone. Chin. Med. J. 2008, 121, 1980-1986.
64. Dunn, L.K.; Mohammad, K.S.; Fournier, P.G.; McKenna, C.R.; Davis, H.W.; Niewolna, M.; Peng, X.H.; Chirgwin, J.M.; Guise, T.A. Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 2009, 4, e6896.
65. Kozlova, N.; Wottawa, M.; Katschinski, D.M.; Kristiansen, G.; Kietzmann, T. Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. Oncotarget 2017, 8, 9885-9898.
66. Nakaoka, H.J.; Tanei, Z.; Hara, T.; Weng, J.S.; Kanamori, A.; Hayashi, T.; Sato, H.; Orimo, A.; Otsuji, K.; Tada, K.; et al. Mint3-mediated L1CAM expression in fibroblasts promotes cancer cell proliferation via integrin α5β1 and tumour growth. Oncogenesis 2017, 6, e334.
67. Shi, L.; He, C.; Li, Z.; Wang, Z.; Zhang, Q. FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1α. Neoplasma 2017, 64, 535-542.
68. Tanaka, T.; Kutomi, G.; Kajiwara, T.; Kukita, K.; Kochin, V.; Kanaseki, T.; Tsukahara, T.; Hirohashi, Y.; Torigoe, T.; Okamoto, Y.; et al. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer. Oncotarget 2017, 8, 24706-24718.
69. Padró, M.; Louie, R.J.; Lananna, B.V.; Krieg, A.J.; Timmerman, L.A.; Chan, D.A. Genome-independent hypoxic repression of estrogen receptor α in breast cancer cells. BMC Cancer 2017, 17, 203.
70. Sun, H.; Zhang, D.; Yao, Z.; Lin, X.; Liu, J.; Gu, Q.; Dong, X.; Liu, F.; Wang, Y.; Yao, N.; et al. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. Cancer Biol. Ther. 2017, 18, 205-213.
71. Tanaka, T.; Ikegami, Y.; Nakazawa, H.; Kuriyama, N.; Oki, M.; Hanai, J.; Sukhatme, V.P.; Kaneki, M. Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. J. Cell. Physiol. 2017, 232, 192-201.
72. Sen, R.; Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986, 46, 705-716.
73. Bandarra, D.; Rocha, S. Tale of two transcription factors: NF-κB and HIF crosstalk. OA Mol. Cell Biol. 2013, 1, 6.
74. D’Ignazio, L.; Bandarra, D.; Rocha, S. NF-κB and HIF crosstalk in immune responses. FEBS J. 2016, 283, 413-424.
75. Balamurugan, K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int. J. Cancer 2016, 138, 1058-1066.
76. Scholz, C.C.; Rodriguez, J.; Pickel, C.; Burr, S.; Fabrizio, J.A.; Nolan, K.A.; Spielmann, P.; Cavadas, M.A.; Crifo, B.; Halligan, D.N.; et al. FIH Regulates Cellular Metabolism through Hydroxylation of the Deubiquitinase OTUB1. PLoS Biol. 2016, 14, e1002347.
77. Melvin, A.; Mudie, S.; Rocha, S. Further insights into the mechanism of hypoxia-induced NF-κB. Cell Cycle 2011, 10, 879-882, Erratum in: Cell Cycle 2011, 10, 2041.
78. Shmakova, A.; Batie, M.; Druker, J.; Rocha, S. Chromatin and oxygen sensing in the context of JmjC histone demethylases. Biochem. J. 2014, 462, 385-395.
79. Zhou, X.; Sun, H.; Chen, H.; Zavadil, J.; Kluz, T.; Arita, A.; Costa, M. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res. 2010, 70, 4214-4221.
80. Prickaerts, P.; Adriaens, M.E.; Beucken, T.V.D.; Koch, E.; Dubois, L.; Dahlmans, V.E.H.; Gits, C.; Evelo, C.T.A.; Chan-Seng-Yue, M.; Wouters, B.G.; et al. Hypoxia increases genome-wide bivalent epigenetic marking by specific gain of H3K27me3. Epigenet. Chromatin 2016, 9, 46.
81. Lu, T.; Yang, M.; Huang, D.B.; Wei, H.; Ozer, G.H.; Ghosh, G.; Stark, G.R. Role of lysine methylation of NF-κB in differential gene regulation. Proc. Natl. Acad. Sci. USA 2013, 110, 13510-13515.
82. Lu, T.; Jackson, M.W.; Wang, B.; Yang, M.; Chance, M.R.; Miyagi, M.; Gudkov, A.V.; Stark, G.R. Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc. Natl. Acad. Sci. USA 2010, 107, 46-51.
83. Batie, M.; Druker, J.; D’Ignazio, L.; Rocha, S. KDM2 Family Members are Regulated by HIF-1 in Hypoxia. Cells 2017, 6, 8.
84. Bandarra, D.; Biddlestone, J.; Mudie, S.; Muller, H.A.; Rocha, S. Hypoxia activates IKK-NF-κB and the immune response in Drosophila melanogaster. Biosci. Rep. 2014, 34, e00127.
85. Booy, E.P.; Henson, E.S.; Gibson, S.B. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011, 30, 2367-2378.
86. Oakes, S.R.; Vaillant, F.; Lim, E.; Lee, L.; Breslin, K.; Feleppa, F.; Deb, S.; Ritchie, M.E.; Takano, E.; Ward, T.; et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc. Natl. Acad. Sci. USA 2012, 109, 2766-2771.
87. Vitagliano, O.; Addeo, R.; D’Angelo, V.; Indolfi, C.; Indolfi, P.; Casale, F. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: Implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev. Hematol. 2013, 6, 587-597.
88. Mortenson, M.M.; Galante, J.G.; Gilad, O.; Schlieman, M.G.; Virudachalam, S.; Kung, H.J.; Bold, R.J. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J. Cell. Biochem. 2007, 102, 1171-1179.
89. Kumar, P.; Ning, Y.; Polverini, P.J. Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab. Investig. 2008, 88, 740-749.
90. Tucker, C.A.; Kapanen, A.I.; Chikh, G.; Hoffman, B.G.; Kyle, A.H.; Wilson, I.M.; Masin, D.; Gascoyne, R.D.; Bally, M.; Klasa, R.J. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels. Mol. Cancer Ther. 2008, 7, 749-758.
91. Mohammad, R.M.; Muqbil, I.; Lowe, L.; Yedjou, C.; Hsu, H.Y.; Lin, L.T.; Siegelin, M.D.; Fimognari, C.; Kumar, N.B.; Dou, Q.P.; et al. Broad targeting of resistance to apoptosis in cancer. Semin. Cancer Biol. 2015, 35, S78-S103.
92. Elfadl, D.; Hodgkinson, V.C.; Long, E.D.; Scaife, L.; Drew, P.J.; Lind, M.J.; Cawkwell, L. A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer. Breast 2011, 20, 334-337.
93. Chen, Y.; Scully, M.; Dawson, G.; Goodwin, C.; Xia, M.; Lu, X.; Kakkar, A. Perturbation of the heparin/heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3K/Akt and MAPK/ERK signalling. Thromb. Haemost. 2013, 109, 1148-1157.
94. Winsel, S.; Mäki-Jouppila, J.; Tambe, M.; Aure, M.R.; Pruikkonen, S.; Salmela, A.L.; Halonen, T.; Leivonen, S.K.; Kallio, L.; Børresen-Dale, A.L.; et al. Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo. Br. J. Cancer 2014, 111, 2142-2151.
95. Koren, S.; Reavie, L.; Couto, J.P.; De Silva, D.; Stadler, M.B.; Roloff, T.; Britschgi, A.; Eichlisberger, T.; Kohler, H.; Aina, O.; et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 2015, 525, 114-118.
96. Singh, R.; Yadav, V.; Kumar, S.; Saini, N. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci. Rep. 2015, 5, 17454.
97. Al Saleh, S.; Al Mulla, F.; Luqmani, Y.A. Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS ONE 2011, 6, e20610.
98. Satram-Maharaj, T.; Nyarko, J.N.; Kuski, K.; Fehr, K.; Pennington, P.R.; Truitt, L.; Freywald, A.; Lukong, K.E.; Anderson, D.H.; Mousseau, D.D. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line. Cell Signal. 2014, 26, 2621-2632.
99. Tan, S.; Ding, K.; Chong, Q.Y.; Zhao, J.; Liu, Y.; Shao, Y.; Zhang, Y.; Yu, Q.; Xiong, Z.; Zhang, W.; et al. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. J. Biol. Chem. 2017, 292, 13551-13564.
100. Nicolini, A.; Ferrari, P.; Biava, P.M.; Carpi, A. Changing the endocrine dependence of breast cancer: Data and hypotheses. Curr. Med. Chem. 2014, 21, 1093-1106.
101. Johnston, S.; Pippen, J., Jr.; Pivot, X.; Lichinitser, M.; Sadeghi, S.; Dieras, V.; Gomez, H.L.; Romieu, G.; Manikhas, A.; Kennedy, M.J.; et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27, 5538-5546.
102. De Melo Gagliato, D.; Jardim, D.L.; Marchesi, M.S.; Hortobagyi, G.N. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget 2016, 7, 64431-64446.
103. Lu, Y.; Zi, X.; Zhao, Y.; Mascarenhas, D.; Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001, 93, 1852-1857.
104. Browne, B.C.; Crown, J.; Venkatesan, N.; Duffy, M.J.; Clynes, M.; Slamon, D.; O’Donovan, N. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann. Oncol. 2011, 22, 68-73.
105. Blumenschein, G.R., Jr.; Mills, G.B.; Gonzalez-Angulo, A.M. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J. Clin. Oncol. 2012, 30, 3287-3296.
106. Zhang, S.; Huang, W.C.; Li, P.; Guo, H.; Poh, S.B.; Brady, S.W.; Xiong, Y.; Tseng, L.M.; Li, S.H.; Ding, Z.; et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 2011, 17, 461-469.
107. Loi, S.; Michiels, S.; Salgado, R.; Sirtaine, N.; Jose, V.; Fumagalli, D.; Kellokumpu-Lehtinen, P.L.; Bono, P.; Kataja, V.; Desmedt, C.; et al. Tumor-infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann. Oncol. 2014, 25, 1544-1550.
108. Wimana, Z.; Gebhart, G.; Guiot, T.; Vanderlinden, B.; Larsimont, D.; Doumont, G.; van Simaeys, G.; Goldman, S.; Flamen, P.; Ghanem, G. N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging. Oncotarget 2017, 8, 56185-56198.
109. Xu, X.; de Angelis, C.; Burke, K.A.; Nardone, A.; Hu, H.; Qin, L.; Veeraraghavan, J.; Sethunath, V.; Heiser, L.M.; Wang, N.; et al. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin. Cancer Res. 2017, 23, 5123-5134.
110. Aghazadeh, S.; Yazdanparast, R. Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN. Biochim. Biophys. Acta 2017, 1861, 1970-1980.
111. Veeraraghavan, J.; de Angelis, C.; Reis-Filho, J.S.; Pascual, T.; Prat, A.; Rimawi, M.F.; Osborne, C.K.; Schiff, R. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 2017, S19-S26.
112. Ocana, A.; Gil-Martin, M.; Martín, M.; Rojo, F.; Antolín, S.; Guerrero, Á.; Trigo, J.M.; Muñoz, M.; Pandiella, A.; Diego, N.G.; et al. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. Oncotarget 2017, 8, 73144-73153.
113. Goldstein, L.J.; Zhao, F.; Wang, M.; Swaby, R.F.; Sparano, J.A.; Meropol, N.J.; Bhalla, K.N.; Pellegrino, C.M.; Katherine Alpaugh, R.; Falkson, C.I.; et al. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Res. Treat. 2017, 165, 375-382.
114. Van Keymeulen, A.; Lee, M.Y.; Ousset, M.; Brohée, S.; Rorive, S.; Giraddi, R.R.; Wuidart, A.; Bouvencourt, G.; Dubois, C.; Salmon, I.; et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 2015, 525, 119-123.
115. Monteiro, F.L.; Vitorino, R.; Wang, J.; Cardoso, H.; Laranjeira, H.; Simões, J.; Caldas, M.; Henrique, R.; Amado, F.; Williams, C.; et al. The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells. Cancer Lett. 2017, 396, 42-52.